Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

British Journal of Haematology

Volumn 152, Issue 1, 2011, Pages 81-88

  Hernández Boluda, Juan Carlos ^a   Alvarez Larrán, Alberto ^b   Gómez, Montse ^a   Angona, Anna ^b   Amat, Paula ^a   Bellosillo, Beatriz ^b   Martínez Avilés, Luz ^b   Navarro, Blanca ^a   Teruel, Anabel ^a   Martínez Ruiz, Francisco ^c   Besses, Carles ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Essential thrombocythaemia; Hydroxycarbamide; Intolerance; Resistance; Response criteria

Indexed keywords

BUSULFAN; HYDROXYUREA; PHOSPHORUS;

ACUTE LEUKEMIA; ADULT; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGY; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOFIBROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG EVALUATION; DRUG RESISTANCE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NUCLEIC ACID SYNTHESIS INHIBITORS; PLATELET COUNT; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650017546     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08430.x     Document Type: Article

References (20)

1. Barbui, T. (2004) The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both. Seminars in Hematology, 41, 15-17.
2. Barosi, G., Besses, C., Birgegard, G., Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J.T., Michiels, J.J. & Barbui, T. (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia, 21, 277-280.
3. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M. & Barbui, T. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 113, 4829-4833.
4. Braester, A. & Quitt, M. (2000) Hydroxyurea as a cause of drug fever. Acta Haematologica, 104, 50-51.
5. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. & Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945-1953.
6. Carobbio, A., Antonioli, E., Guglielmelli, P., Vannucchi, A.M., Delaini, F., Guerini, V., Finazzi, G., Rambaldi, A. & Barbui, T. (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. Journal of Clinical Oncology, 26, 2732-2736.
7. Carobbio, A., Finazzi, G., Antonioli, E., Vannucchi, A.M., Barosi, G., Ruggeri, M., Rodeghiero, F., Delaini, F., Rambaldi, A. & Barbui, T. (2010) Hydroxyurea in essential thrombocytemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood, 116, 1051-1055.
8. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New England Journal of Medicine, 332, 1132-1136.
9. Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 101, 3749.
10. Gangat, N., Wolanskyj, A.P., McClure, R.F., Li, C.Y., Schwager, S., Wu, W. & Tefferi, A. (2007) Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia, 21, 270-276.
11. Girodon, F., Dutrillaux, F., Broseus, J., Mounier, M., Goussot, V., Bardonnaud, P., Chretien, M.L. & Maynadie, M. (2010) Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients. Leukemia, 24, 900-903.
12. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., Van Der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. & Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33-45.
13. Lofvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematology, 41, 375-381.
14. Murphy, S., Iland, H., Rosenthal, D. & Laszlo, J. (1986) Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Seminars in Hematology, 23, 177-182.
15. Palandri, F., Catani, L., Testoni, N., Ottaviani, E., Polverelli, N., Fiacchini, M., De Vivo, A., Salmi, F., Lucchesi, A., Baccarani, M. & Vianelli, N. (2009) Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. American Journal of Hematology, 84, 215-220.
16. Randi, M.L., Ruzzon, E., Luzzatto, G., Tezza, F., Girolami, A. & Fabris, F. (2005) Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica, 90, 261-262.
17. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
18. Thiele, J., Kvasnicka, H.M., Facchetti, F., Franco, V., Van Der Walt, J. & Orazi, A. (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica, 90, 1128-1132.
19. Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. & Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159-166.
20. Young, C.W., Schochetman, G. & Karnofsky, D.A. (1967) Hydroxyurea-induced inhibition of deoxyribonucleotide synthesis: studies in intact cells. Cancer Research, 27, 526-534.